Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Cardiovasc Drugs Ther ; 32(6): 639-641, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30232658

RESUMEN

The original version of this article unfortunately contained a mistake. In Table 2, the frequency of Septic Shock reported just below the frequency of "At least 1 Episode of VAP" actually corresponds to the First (and not the Second) Episode of VAP during the postresuscitation period.

2.
Cardiovasc Drugs Ther ; 32(4): 339-351, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-30084038

RESUMEN

PURPOSE: Low-dose steroids may reduce the mortality of severely ill patients with septic shock. We sought to determine whether exposure to stress-dose steroids during and/or after cardiopulmonary resuscitation is associated with reduced risk of death due to postresuscitation septic shock. METHODS: We analyzed pooled, individual patient data from two prior, randomized clinical trials (RCTs). RCTs evaluated vasopressin, steroids, and epinephrine (VSE) during resuscitation and stress-dose steroids after resuscitation in vasopressor-requiring, in-hospital cardiac arrest. In the second RCT, 15 control group patients received open-label, stress-dose steroids. Patients with postresuscitation shock were assigned to a Steroids (n = 118) or No Steroids (n = 73) group according to an "as-treated" principle. We used cumulative incidence competing risks Cox regression to determine cause-specific hazard ratios (CSHRs) for pre-specified predictors of lethal septic shock (primary outcome). In sensitivity analyses, data were analyzed according to the intention-to-treat (ITT) principle (VSE group, n = 103; control group, n = 88). RESULTS: Lethal septic shock was less likely in Steroids versus No Steroids group, CSHR, 0.40, 95% confidence interval (CI), 0.20-0.82; p = 0.012. ITT analysis yielded similar results: VSE versus Control, CSHR, 0.44, 95% CI, 0.23-0.87; p = 0.019. Adjustment for significant, between-group baseline differences in composite cardiac arrest causes such as "hypotension and/or myocardial ischemia" did not appreciably affect the aforementioned CSHRs. CONCLUSIONS: In this reanalysis, exposure to stress-dose steroids (primarily in the context of a combined VSE intervention) was associated with lower risk of postresuscitation lethal septic shock.


Asunto(s)
Reanimación Cardiopulmonar/efectos adversos , Epinefrina/administración & dosificación , Paro Cardíaco/terapia , Admisión del Paciente , Choque Séptico/prevención & control , Esteroides/administración & dosificación , Vasopresinas/administración & dosificación , Anciano , Reanimación Cardiopulmonar/mortalidad , Combinación de Medicamentos , Epinefrina/efectos adversos , Femenino , Paro Cardíaco/diagnóstico , Paro Cardíaco/mortalidad , Paro Cardíaco/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Factores Protectores , Ensayos Clínicos Controlados Aleatorios como Asunto , Estudios Retrospectivos , Factores de Riesgo , Choque Séptico/diagnóstico , Choque Séptico/microbiología , Choque Séptico/mortalidad , Esteroides/efectos adversos , Factores de Tiempo , Resultado del Tratamiento , Vasopresinas/efectos adversos
3.
Am J Emerg Med ; 32(12): 1559.e1-3, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24972961

RESUMEN

Spontaneous retroperitoneal hematoma (SRH) is a severe and potentially fatal complication of anticoagulation therapy. We describe a case of fatal spontaneous massive retroperitoneal hematoma in a female patient receiving bridging therapy with enoxaparin for atrial fibrillation. Physicians should be cautious when prescribing enoxaparin in elderly patients, in patients with impaired renal function, and in patients receiving concomitant oral anticoagulants. Emergency physicians should always consider SRH in the differential diagnosis in patients under enoxaparin therapy presenting with abdominal pain. Computed tomographic scan is the imaging modality of choice for evaluating SRH. Early diagnosis and aggressive treatment are of paramount importance as SRH is associated with high mortality and morbidity rates.


Asunto(s)
Anticoagulantes/efectos adversos , Enoxaparina/efectos adversos , Hematoma/inducido químicamente , Espacio Retroperitoneal , Anciano , Anticoagulantes/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Enoxaparina/uso terapéutico , Resultado Fatal , Femenino , Hematoma/diagnóstico por imagen , Humanos , Espacio Retroperitoneal/diagnóstico por imagen , Tomografía Computarizada por Rayos X
4.
JAMA ; 310(3): 270-9, 2013 Jul 17.
Artículo en Inglés | MEDLINE | ID: mdl-23860985

RESUMEN

IMPORTANCE: Among patients with cardiac arrest, preliminary data have shown improved return of spontaneous circulation and survival to hospital discharge with the vasopressin-steroids-epinephrine (VSE) combination. OBJECTIVE: To determine whether combined vasopressin-epinephrine during cardiopulmonary resuscitation (CPR) and corticosteroid supplementation during and after CPR improve survival to hospital discharge with a Cerebral Performance Category (CPC) score of 1 or 2 in vasopressor-requiring, in-hospital cardiac arrest. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled, parallel-group trial performed from September 1, 2008, to October 1, 2010, in 3 Greek tertiary care centers (2400 beds) with 268 consecutive patients with cardiac arrest requiring epinephrine according to resuscitation guidelines (from 364 patients assessed for eligibility). INTERVENTIONS: Patients received either vasopressin (20 IU/CPR cycle) plus epinephrine (1 mg/CPR cycle; cycle duration approximately 3 minutes) (VSE group, n = 130) or saline placebo plus epinephrine (1 mg/CPR cycle; cycle duration approximately 3 minutes) (control group, n = 138) for the first 5 CPR cycles after randomization, followed by additional epinephrine if needed. During the first CPR cycle after randomization, patients in the VSE group received methylprednisolone (40 mg) and patients in the control group received saline placebo. Shock after resuscitation was treated with stress-dose hydrocortisone (300 mg daily for 7 days maximum and gradual taper) (VSE group, n = 76) or saline placebo (control group, n = 73). MAIN OUTCOMES AND MEASURES: Return of spontaneous circulation (ROSC) for 20 minutes or longer and survival to hospital discharge with a CPC score of 1 or 2. RESULTS: Follow-up was completed in all resuscitated patients. Patients in the VSE group vs patients in the control group had higher probability for ROSC of 20 minutes or longer (109/130 [83.9%] vs 91/138 [65.9%]; odds ratio [OR], 2.98; 95% CI, 1.39-6.40; P = .005) and survival to hospital discharge with CPC score of 1 or 2 (18/130 [13.9%] vs 7/138 [5.1%]; OR, 3.28; 95% CI, 1.17-9.20; P = .02). Patients in the VSE group with postresuscitation shock vs corresponding patients in the control group had higher probability for survival to hospital discharge with CPC scores of 1 or 2 (16/76 [21.1%] vs 6/73 [8.2%]; OR, 3.74; 95% CI, 1.20-11.62; P = .02), improved hemodynamics and central venous oxygen saturation, and less organ dysfunction. Adverse event rates were similar in the 2 groups. CONCLUSION AND RELEVANCE: Among patients with cardiac arrest requiring vasopressors, combined vasopressin-epinephrine and methylprednisolone during CPR and stress-dose hydrocortisone in postresuscitation shock, compared with epinephrine/saline placebo, resulted in improved survival to hospital discharge with favorable neurological status. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00729794.


Asunto(s)
Agonistas Adrenérgicos beta/uso terapéutico , Epinefrina/uso terapéutico , Paro Cardíaco/complicaciones , Paro Cardíaco/terapia , Hemostáticos/uso terapéutico , Metilprednisolona/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Vasopresinas/uso terapéutico , Anciano , Anciano de 80 o más Años , Encéfalo/fisiopatología , Reanimación Cardiopulmonar , Método Doble Ciego , Quimioterapia Combinada , Femenino , Escala de Consecuencias de Glasgow , Humanos , Hidrocortisona/uso terapéutico , Pacientes Internos , Masculino , Persona de Mediana Edad , Alta del Paciente , Choque/tratamiento farmacológico , Choque/etiología , Análisis de Supervivencia , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA